FDA Orange Book

Generic for Avage

Avage contains tazarotene. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.

Source: FDA Orange Book data file dated 2026-10-09. Publisher page

Yes. The generic name for Avage is tazarotene. 2 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.

Run it in Rivvi

Map Avage and your other top fills to their generics

Every strength in RxNorm, with brands that have no generic flagged.

Build the map

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Avage products in the Orange Book

Avage products and approved generics
Form and routeStrengthBrand statusBrand TEActive genericsGeneric TE codes
cream, topical0.1%Marketed (Rx)AB2AB

NDA 021184, held by CHARTWELL RX SCIENCES LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.

Approved generic tazarotene

Approved generic versions of Avage
CompanyANDATE codeApprovedStrengths
SUN PHARMA CANADA INC208258AB (A-rated, therapeutically equivalent)April 3, 20170.1%
COSETTE PHARMACEUTICALS NC LABORATORIES LLC208662AB (A-rated, therapeutically equivalent)December 22, 20170.1%

Avage NDC codes

Questions

Is there a generic for Avage?

Yes. The generic name for Avage is tazarotene. 2 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.

What is the generic name for Avage?

The active ingredient in Avage is tazarotene, per the FDA Orange Book.

What does a therapeutic equivalence code mean?

In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.

More on Avage and Tazarotene

Try it on your own data today.

Free to start. Most teams are using it the same day.